Stada Arzneimittel Aktiengesellschaft Stock Profit Margin
STADA Arzneimittel Aktiengesellschaft fundamentals help investors to digest information that contributes to STADA Arzneimittel's financial success or failures. It also enables traders to predict the movement of STADA OTC Stock. The fundamental analysis module provides a way to measure STADA Arzneimittel's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to STADA Arzneimittel otc stock.
STADA |
STADA Arzneimittel Aktiengesellschaft OTC Stock Profit Margin Analysis
STADA Arzneimittel's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current STADA Arzneimittel Profit Margin | 9.00 % |
Most of STADA Arzneimittel's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, STADA Arzneimittel Aktiengesellschaft is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, STADA Arzneimittel Aktiengesellschaft has a Profit Margin of 9.0%. This is 180.29% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is notably lower than that of the firm.
STADA Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses STADA Arzneimittel's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of STADA Arzneimittel could also be used in its relative valuation, which is a method of valuing STADA Arzneimittel by comparing valuation metrics of similar companies.STADA Arzneimittel is currently under evaluation in profit margin category among related companies.
STADA Fundamentals
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 | |||
| Profit Margin | 9.00 % | |||
| Current Valuation | 6.87 B | |||
| Shares Outstanding | 62.26 M | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 22.46 X | |||
| Price To Book | 4.54 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 2.69 B | |||
| Gross Profit | 1.37 B | |||
| EBITDA | 559.98 M | |||
| Net Income | 252.03 M | |||
| Cash And Equivalents | 502.02 M | |||
| Cash Per Share | 8.06 X | |||
| Total Debt | 1.73 B | |||
| Debt To Equity | 2.58 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 20.02 X | |||
| Cash Flow From Operations | 347.14 M | |||
| Earnings Per Share | 4.05 X | |||
| Number Of Employees | 12.34 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 6.87 B | |||
| Total Asset | 3.46 B | |||
| Retained Earnings | 686 M | |||
| Working Capital | 604 M | |||
| Current Asset | 1.49 B | |||
| Current Liabilities | 887 M | |||
| Z Score | 1.8 | |||
| Last Dividend Paid | 0.11 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in STADA OTC Stock
If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |